242 related articles for article (PubMed ID: 23869764)
21. Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5.
Shi W; Yang J; Li S; Shan X; Liu X; Hua H; Zhao C; Feng Z; Cai Z; Zhang L; Zhou D
Oncotarget; 2015 Nov; 6(37):40172-85. PubMed ID: 26474386
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.
Mori A; Moser C; Lang SA; Hackl C; Gottfried E; Kreutz M; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Res; 2009 Aug; 7(8):1390-8. PubMed ID: 19671674
[TBL] [Abstract][Full Text] [Related]
23. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.
Weng D; Song X; Xing H; Ma X; Xia X; Weng Y; Zhou J; Xu G; Meng L; Zhu T; Wang S; Ma D
Cancer Lett; 2009 Jan; 273(2):257-65. PubMed ID: 18842333
[TBL] [Abstract][Full Text] [Related]
24. Effect of shRNA targeting survivin on ovarian cancer.
Xing J; Jia CR; Wang Y; Guo J; Cai Y
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1221-9. PubMed ID: 22426961
[TBL] [Abstract][Full Text] [Related]
25. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
26. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
[TBL] [Abstract][Full Text] [Related]
27. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C
Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233
[TBL] [Abstract][Full Text] [Related]
28. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
29. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
Luo X; Dong Z; Chen Y; Yang L; Lai D
Cell Prolif; 2013 Aug; 46(4):436-46. PubMed ID: 23869765
[TBL] [Abstract][Full Text] [Related]
30. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
[TBL] [Abstract][Full Text] [Related]
31. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
[TBL] [Abstract][Full Text] [Related]
32. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
[TBL] [Abstract][Full Text] [Related]
33. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
[TBL] [Abstract][Full Text] [Related]
34. KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy.
Jia J; Zhang HB; Shi Q; Yang C; Ma JB; Jin B; Wang X; He D; Guo P
Theranostics; 2019; 9(19):5464-5477. PubMed ID: 31534497
[TBL] [Abstract][Full Text] [Related]
35. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
Jiang L; Luo RY; Yang J; Cheng YX
Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
[TBL] [Abstract][Full Text] [Related]
37. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of survivin is a factor responsible for differential responses of ovarian cancer cells to S-allylmercaptocysteine (SAMC).
Wu J; Zhao S; Zhang J; Qu X; Jiang S; Zhong Z; Zhang F; Wong Y; Chen H
Exp Mol Pathol; 2016 Apr; 100(2):294-302. PubMed ID: 26896649
[TBL] [Abstract][Full Text] [Related]
39. [Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity].
Peng LP; Huang JM; Zhang GN; Zha X; Ren Y; Fan Y; Deng BF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):860-4. PubMed ID: 21211287
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
